Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.51 |
| ▸ | RARG | P13631 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18205745 | 0.91 | RORC (0.52) | RORCRARGELANEMAOBMAPT | |
| SCHEMBL18205758 | 0.90 | RORC (0.44) | RORCRARGELANEMAOBMAPT | |
| SCHEMBL16797277 | 0.85 | RORC (0.71) | RORCRARGELANEALDH1A1CYP3A4 | |
| SCHEMBL16797161 | 0.84 | RORC (0.70) | RORCRARGCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16797124 | 0.83 | RORC (0.52) | RORCRARGMAPTPOLBALDH1A1 | |
| SCHEMBL18212245 | 0.82 | RORC (0.61) | RORCRARGCYP3A4CYP2C9 | |
| SCHEMBL17977788 | 0.77 | RORC (0.44) | RORCMAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL16797175 | 0.77 | RORC (0.63) | RORCRARGELANECYP3A4CYP2C9 | |
| SCHEMBL18268163 | 0.76 | RORC (0.43) | RORCRARGELANEMAPTRXFP1 | |
| SCHEMBL18205749 | 0.76 | RORC (0.68) | RORCRARGCYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080090-B1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2018-01-31 | — | — | EP | disclosed |
| US-9682977-B2 | Bicyclic heteroaryl indole analogues useful as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20160326163-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-11-10 | — | — | US | disclosed |
| EP-3080090-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015087234-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326163-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | RORA, RORB, RORC | RORC 3/4885RARG 27/4885ELANE 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.